These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34390114)

  • 21. Valproate-induced Periorbital Edema.
    Hatahet S; Khalaf K; Elhamamsy S
    R I Med J (2013); 2021 Dec; 104(10):10-11. PubMed ID: 34846373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive review of the psychiatric uses of valproate.
    Davis LL; Ryan W; Adinoff B; Petty F
    J Clin Psychopharmacol; 2000 Feb; 20(1 Suppl 1):1S-17S. PubMed ID: 10646685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.
    Tariot PN; Schneider LS; Cummings J; Thomas RG; Raman R; Jakimovich LJ; Loy R; Bartocci B; Fleisher A; Ismail MS; Porsteinsson A; Weiner M; Jack CR; Thal L; Aisen PS;
    Arch Gen Psychiatry; 2011 Aug; 68(8):853-61. PubMed ID: 21810649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperammonemia associated with valproic acid use in elderly psychiatric patients.
    Holroyd S; Overdyke JT
    J Neuropsychiatry Clin Neurosci; 2012; 24(3):372-4. PubMed ID: 23037652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of valproic acid versus haloperidol in patients with acute agitation: results of a randomized, double-blind, parallel-group trial.
    Asadollahi S; Heidari K; Hatamabadi H; Vafaee R; Yunesian S; Azadbakht A; Mirmohseni L
    Int Clin Psychopharmacol; 2015 May; 30(3):142-50. PubMed ID: 25500684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of anticonvulsants in treating agitated demented elderly patients.
    Grossman F
    Pharmacotherapy; 1998; 18(3):600-6. PubMed ID: 9620110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paradoxical Agitation in Adolescent Male on Valproate.
    Avari JM
    J Child Adolesc Psychopharmacol; 2016 Feb; 26(1):78-9. PubMed ID: 26789824
    [No Abstract]   [Full Text] [Related]  

  • 28. Reversible dementia and apparent brain atrophy during valproate therapy.
    Papazian O; Cañizales E; Alfonso I; Archila R; Duchowny M; Aicardi J
    Ann Neurol; 1995 Oct; 38(4):687-91. PubMed ID: 7574471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Divalproex sodium for the treatment of behavioural problems associated with dementia in the elderly.
    Porsteinsson AP
    Drugs Aging; 2006; 23(11):877-86. PubMed ID: 17109566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Inappropriate antidiuretic hormone secretion induced by sodium valproate].
    Bève E; Beck E; Pinto E; Ansseau M
    Rev Med Liege; 2010 Jan; 65(1):6-9. PubMed ID: 20222501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutropenia associated with the comedication of quetiapine and valproate in 2 elderly patients.
    Hung WC; Hsieh MH
    J Clin Psychopharmacol; 2012 Jun; 32(3):416-7. PubMed ID: 22561472
    [No Abstract]   [Full Text] [Related]  

  • 32. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents.
    Brigo F; Igwe SC; Lattanzi S
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD003032. PubMed ID: 33475151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Placebo-controlled study of divalproex sodium for agitation in dementia.
    Porsteinsson AP; Tariot PN; Erb R; Cox C; Smith E; Jakimovich L; Noviasky J; Kowalski N; Holt CJ; Irvine C
    Am J Geriatr Psychiatry; 2001; 9(1):58-66. PubMed ID: 11156753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents.
    Brigo F; Igwe SC; Lattanzi S
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD003032. PubMed ID: 30734919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Valproate-caused encephalopathy].
    Thygesen KS; Wolf P
    Ugeskr Laeger; 2005 Oct; 167(40):3793-4. PubMed ID: 16221398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Valproate-induced Hyperammonemic Encephalopathy Presenting as Catatonia.
    Pérez-Esparza R; Oñate-Cadena N; Ramírez-Bermúdez J; Espínola-Nadurille M
    Neurologist; 2018 Mar; 23(2):51-52. PubMed ID: 29494435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and pathophysiological characteristics of valproate-induced pleural effusion.
    Tryfon S; Papadopoulou E; Saroglou M; Vlachopoulos D; Georgopoulou A; Serasli E; Ismailos G
    Clin Toxicol (Phila); 2021 Oct; 59(10):869-876. PubMed ID: 34259092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gabapentin in the treatment of dementia-associated nocturnal agitation.
    Buskova J; Busek P; Nevsimalova S
    Med Sci Monit; 2011 Dec; 17(12):CS149-51. PubMed ID: 22129906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lessons learned from the discovery of sodium valproate and what has this meant to future drug discovery efforts?
    Janković SM; Janković SV
    Expert Opin Drug Discov; 2020 Nov; 15(11):1355-1364. PubMed ID: 32686964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Valproate for agitation in critically ill patients: A retrospective study.
    Gagnon DJ; Fontaine GV; Smith KE; Riker RR; Miller RR; Lerwick PA; Lucas FL; Dziodzio JT; Sihler KC; Fraser GL
    J Crit Care; 2017 Feb; 37():119-125. PubMed ID: 27693975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.